Cathy Eng, VICC Associate Dir, Strategic Relations and Research Partnerships at Vanderbilt-Ingram Cancer, shared a post on LinkedIn:
“Out of press: ORIGAMI-1 In the Journal of Clinical Oncology American Society of Clinical Oncology (ASCO): The role of Amivantamab the fully human, bispecific IgG1 monoclonal antibody that simultaneously targets EGFR and MET in met colorectal cancer!”
Title: Amivantamab Monotherapy in Chemorefractory RAS/BRAFWild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study
Authors: Paul E. Oberstein, J. Randolph Hecht, Kanwal Raghav, Filippo Pietrantonio, Dirk Arnold, Victor Moreno, Eric Van Cutsem, Rozita Abdul Malik, Yong Sang Hong, Myung Ah Lee, Harvey Yu-Li Su, Jeeyun Lee, Sreenivasa Chandana, Marcia Cruz-Correa, Ying Yuan, Azura Ahmad, Kuan-Ming Lai, Hung-Chih Hsu, Eric Xueyu Chen, Elena Elez, Chia-Chi Lin, Carlos Lopez, Hans Prenen, Susana Roselló-Keränen, Hector Velez, Yu-Min Yeh, Volker Heinemann, Cathy Eng, Seung-Hoon Beom, Sabine Tejpar, Sanjib Chowdhury, Xuesong Lyu, Medha Kamat, Joshua C. Curtin, Bharvin Patel, John Xie, Rianka Bhattacharya, Robert W. Schnepp, Emrullah Yilmaz, Ryota Iwasawa, Mahesh Daksh, Patricia Lorenzini, Meena Thayu, Mahadi Baig, Han Sang Kim, Sae-Won Han
Read the Full Article.
Other articles about Cathy Eng on OncoDaily.